2018
DOI: 10.1097/hrp.0000000000000198
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background Pain comorbid with depression is frequently encountered in clinical settings and often leads to significant impaired functioning. Given the complexity of comorbidities, it is important to address both pain and depressive symptoms when evaluating treatment options. Aim To review studies addressing pain comorbid with depression, and to report the impact of current treatments. Method A systematic sea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
143
0
5

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 297 publications
(153 citation statements)
references
References 47 publications
5
143
0
5
Order By: Relevance
“…11 Our bidirectional analyses, with genetic liability for prescription opioid use as an outcome, point to genetic liability for MDD but not ASRD as a possible causal risk factor of opioid use in psychiatric populations. Depression severity has been shown to be associated with increasing likelihood of misusing opioid medications for nonpain symptoms and selfincreasing opioid dosage 58 and up to 30% of long-term opioid users who have MDD qualify for moderate-to-severe OUD, 15,59 suggesting that targeting opioid use prevention for patients with MDD may help mitigate the US opioid epidemic. 1,10 Given more than half of individuals with OUD have comorbid MDD, 10 the increased use of opioids by individuals with MDD may be owing to self-medication of social or emotional pain, 11 suggesting that the development of thera-peutic interventions with minimal risk targeted at endogenous opioid dysregulation represents another important prevention opportunity.…”
Section: Discussionmentioning
confidence: 99%
“…11 Our bidirectional analyses, with genetic liability for prescription opioid use as an outcome, point to genetic liability for MDD but not ASRD as a possible causal risk factor of opioid use in psychiatric populations. Depression severity has been shown to be associated with increasing likelihood of misusing opioid medications for nonpain symptoms and selfincreasing opioid dosage 58 and up to 30% of long-term opioid users who have MDD qualify for moderate-to-severe OUD, 15,59 suggesting that targeting opioid use prevention for patients with MDD may help mitigate the US opioid epidemic. 1,10 Given more than half of individuals with OUD have comorbid MDD, 10 the increased use of opioids by individuals with MDD may be owing to self-medication of social or emotional pain, 11 suggesting that the development of thera-peutic interventions with minimal risk targeted at endogenous opioid dysregulation represents another important prevention opportunity.…”
Section: Discussionmentioning
confidence: 99%
“…Serotonin noradrenaline reuptake inhibitors (SNRIs; e.g., duloxetine) and selective serotonin reuptake inhibitors (SSRIs; e.g., paroxetine, sertraline) are commonly used antidepressants for the treatment of comorbid chronic pain and depression (60). Other antidepressant options include tricyclic antidepressants (TCAs) such as amitriptyline (61,62).…”
Section: Introductionmentioning
confidence: 99%
“…Other antidepressant options include tricyclic antidepressants (TCAs) such as amitriptyline (61,62). While these medications have been found to reduce the symptoms of both depression and pain partially, no significant differences in efficacy between them have been established so far (63), thus further research is required (60,64). For example, the efficacy of TCAs against other antidepressants for the treatment of comorbid chronic pain and depression remains unclear due to a lack of rigorous studies (35,65,66).…”
Section: Introductionmentioning
confidence: 99%
“…As the number of MM conditions increase from one to five, the proportion of residents reporting mild pain decreases to zero among residents with 5 MM conditions. Several factors are known to contribute to pain intensity and frequency; most notably, depression and anxiety (see 43 IsHak, Wen, Naghechi, Vanle, Dang, Knsop et al, 2018 for a recent review), musculoskeletal problems, 40,44 and cardiovascular diseases; 45 unfortunately, the interaction between chronic pain and CCD is not well understood. There is evidence, however, that management of CCD patients can become increasingly more challenging when patients also experience chronic pain, due to complications associated with medication dosing and interactions among multiple diseases.…”
mentioning
confidence: 99%